This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
BMC Cancer Open Access 24 September 2022
-
Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study
Investigational New Drugs Open Access 14 July 2022
-
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
BMC Hematology Open Access 31 January 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11: 3604–3608.
Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011; 117: 2690–2696.
Thorpe M, Montalvao A, Pierdomenico F, Moita F, Almeida A . Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res 2012; 36: 1071–1073.
Ades L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 2013; 37: 609–613.
Cheson B, Greenberg P, Bennett J, Lowenberg B, Wijermans P, Nimer S et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn. IARC Press: Lyon, France, 2008.
Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996; 88: 2480–2487.
Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182–6192.
Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722–726.
Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012; 119: 1208–1213.
Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011; 118: 3824–3831.
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57.
Acknowledgements
This trial was funded by Cancer Research UK (Grant Award Number C24417/A10418) and Celgene (UK) Ltd. Celgene (UK) provided study drug. Methylation studies were funded by a grant from Yorkshire Cancer Research (Grant Award Number L335) and on-going support from Leukaemia & Lymphoma Research, UK. We would like to thank staff at the 13 UK centres who recruited patients to this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
MWD, JK and DTB have received advisory board and speaker fees from Celgene. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Drummond, M., Pocock, C., Boissinot, M. et al. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia 28, 1570–1572 (2014). https://doi.org/10.1038/leu.2014.85
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.85
This article is cited by
-
Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study
Investigational New Drugs (2022)
-
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
BMC Cancer (2022)
-
Clinical update on hypomethylating agents
International Journal of Hematology (2019)
-
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
BMC Hematology (2018)
-
Therapy for Chronic Myelomonocytic Leukemia in a New Era
Current Hematologic Malignancy Reports (2017)